Literature DB >> 15364413

Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer's disease.

Claire-Marie Dhaenens1, Edwige Van Brussel, Susanna Schraen-Maschke, Florence Pasquier, André Delacourte, Bernard Sablonnière.   

Abstract

The transport of amyloid precursor protein is mediated through its interaction with kinesin light-chain 1 (KNS2). We hypothesized that kinesin light-chain dysfunction might be involved in the pathogenesis of Alzheimer's disease (AD). To assess the physiological relevance of an allelic variation in the KNS2 gene, the association analysis of three single nucleotide polymorphisms (SNPs) in the 5'UTR or in intronic sequences of KNS2 gene were performed in 100 AD brain patients and in 103 controls. For one of these polymorphisms (G58836C in intron 13), the association between AD and the C allele was found to be significant (odds ratio = 1.73, 95% CI: 1.12-2.67, P = 0.012). No synergistic effects were found between the APOE epsilon 4 allele and KNS2 gene polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364413     DOI: 10.1016/j.neulet.2004.07.040

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

Review 2.  Nanoparticles in the brain: a potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases.

Authors:  Shermali Gunawardena
Journal:  Pharm Res       Date:  2013-04-27       Impact factor: 4.200

3.  A cytoskeleton motor protein genetic variant may exert a protective effect on the occurrence of multiple sclerosis: the janus face of the kinesin light-chain 1 56836CC genetic variant.

Authors:  Zoltan Szolnoki; Andras Kondacs; Yvette Mandi; Ferenc Somogyvari
Journal:  Neuromolecular Med       Date:  2007-10-13       Impact factor: 3.843

4.  A genetic variant in cytoskeleton motors amplifies susceptibility to leukoaraiosis in hypertensive smokers: gene-environmental interactions behind vascular white matter demyelinization.

Authors:  Zoltan Szolnoki; Andras Kondacs; Yvette Mandi; Ferenc Somogyvari
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

5.  Kinesin light chain 1 gene haplotypes in three conformational diseases.

Authors:  Malin von Otter; Sara Landgren; Staffan Nilsson; Caroline Lundvall; Lennart Minthon; Nenad Bogdanovic; Niels Andreasen; Deborah R Gustafson; Ingmar Skoog; Anders Wallin; Anna Håkansson; Hans Nissbrandt; Madeleine Zetterberg; Gunnar Tasa; Kaj Blennow; Henrik Zetterberg
Journal:  Neuromolecular Med       Date:  2009-11-13       Impact factor: 3.843

Review 6.  The Beta-amyloid protein of Alzheimer's disease: communication breakdown by modifying the neuronal cytoskeleton.

Authors:  Sara H Mokhtar; Maha M Bakhuraysah; David S Cram; Steven Petratos
Journal:  Int J Alzheimers Dis       Date:  2013-12-12

7.  The link between apolipoprotein E, presenilin 1, and kinesin light chain 1 gene polymorphisms and age-related cortical cataracts in the Chinese population.

Authors:  Min Wu; Can Zheng; Rong-Di Yuan; Min Sun; Yan Xu; Jian Ye
Journal:  Mol Vis       Date:  2015-04-10       Impact factor: 2.367

8.  Variability in the kinesin light chain 1 gene may influence risk of age-related cataract.

Authors:  Malin E Andersson; Madeleine Zetterberg; Gunnar Tasa; Mona Seibt-Palmér; Erkki Juronen; Pait Teesalu; Kaj Blennow; Henrik Zetterberg
Journal:  Mol Vis       Date:  2007-06-27       Impact factor: 2.367

9.  δ-Catenin is genetically and biologically associated with cortical cataract and future Alzheimer-related structural and functional brain changes.

Authors:  Gyungah Jun; Juliet A Moncaster; Carolina Koutras; Sudha Seshadri; Jacqueline Buros; Ann C McKee; Georges Levesque; Philip A Wolf; Peter St George-Hyslop; Lee E Goldstein; Lindsay A Farrer
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

Review 10.  Axonal Transport and Neurodegeneration: How Marine Drugs Can Be Used for the Development of Therapeutics.

Authors:  Joseph A White; Rupkatha Banerjee; Shermali Gunawardena
Journal:  Mar Drugs       Date:  2016-05-19       Impact factor: 5.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.